As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of BioAge Labs, Inc. The largest reported stake is Kristen Fortney's, at 7.2%. 9 filings are on record since August 14, 2025 (Schedule 13G/A, February 13, 2026).
Sell to companies like BioAge Labs, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Cormorant Asset Management, LP · Sole voting: 0 · Shared voting: 2,390,605 · Sole dispositive: 0 · Shared dispositive: 2,390,605 · SCHEDULE 13G/A, 2026-08-14
- · Holder: VK Services, LLC · Percent: 4% · Shares: 1,798,702 · SCHEDULE 13G/A
- · Holder: Cormorant Asset Management, LP · Percent: 6.51% · SCHEDULE 13G/A
- · Reporting person: BlackRock, Inc. · Sole voting: 2,208,192 · Shared voting: 0 · Sole dispositive: 2,236,460 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-27
- · Holder: ADAR1 Capital Management, LLC · Percent: 0.4% · SCHEDULE 13G/A
BioAge Labs, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 7.2% | 2,704,736 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 | |
| Cormorant Asset Management, LP | 5.38% | 2,390,605 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 5.03% | 2,236,460 | SCHEDULE 13G, 2026-04-27 | 2026-03-31 |
| VK Services, LLC | 4% | 1,798,702 | SCHEDULE 13G/A, 2026-05-15 | 2026-05-15 |
| ADAR1 Capital Management, LLC | 0.4% | 135,560 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind BioAge Labs, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on BioAge Labs, Inc. and the records around it.
BioAge Labs, Inc. elsewhere on the record
Companies that share a holder
- Khosla Ventures VI, LP also filed stake reports on 2 other companies: Faeth Therapeutics, Inc. (Aug 2026), Serve Robotics Inc. (Sep 2025)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), Bright Minds Biosciences Inc. (Aug 2026)
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
Watch BioAge Labs, Inc.
Get an email when BioAge Labs, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioAge Labs, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioAge Labs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioAge Labs, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 0 | 2,390,605 | 0 | 2,390,605 | SCHEDULE 13G/A, 2026-08-14 |
| Bihua Chen | 0 | 2,390,605 | 0 | 2,390,605 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 2,208,192 | 0 | 2,236,460 | 0 | SCHEDULE 13G, 2026-04-27 |
| Khosla Ventures VI, LP | 0 | 437,152 | 0 | 437,152 | SCHEDULE 13G/A, 2026-05-15 |
| Khosla Ventures Opportunity I, LP | 0 | 1,361,550 | 0 | 1,361,550 | SCHEDULE 13G/A, 2026-05-15 |
| Khosla Ventures Associates VI, LLC | 0 | 437,152 | 0 | 437,152 | SCHEDULE 13G/A, 2026-05-15 |
| Khosla Ventures Opportunity Associates I, LLC | 0 | 1,361,550 | 0 | 1,361,550 | SCHEDULE 13G/A, 2026-05-15 |
| VK Services, LLC | 0 | 1,798,702 | 0 | 1,798,702 | SCHEDULE 13G/A, 2026-05-15 |
| Vinod Khosla | 0 | 1,798,702 | 0 | 1,798,702 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies BioAge Labs, Inc. by CUSIP 09077V100 and gives its principal executive office as 5885 Hollis Street, Suite 370, Emeryville, CA 94608 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
See responses to Item 11 on the attached cover pages, which are calculated based on 44,452,734 shares of Common Stock outstanding as of May 1, 2026, which is the total number of shares of Common Stock outstanding as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on May 8, 2026.VK Services, LLC, SCHEDULE 13G/A, 2026-05-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | ADAR1 Capital Management, LLC | 5.4% | SCHEDULE 13G |
| 2025-08-14 | Cormorant Asset Management, LP | 5.97% | SCHEDULE 13G/A |
| 2026-02-13 | Kristen Fortney | 7.2% | SCHEDULE 13G/A |
| 2026-02-17 | ADAR1 Capital Management, LLC | 0.4% | SCHEDULE 13G/A |
| 2026-02-17 | Cormorant Asset Management, LP | 5.69% | SCHEDULE 13G/A |
| 2026-04-27 | BlackRock, Inc. | 5.03% | SCHEDULE 13G |
| 2026-05-15 | Cormorant Asset Management, LP | 6.51% | SCHEDULE 13G/A |
| 2026-05-15 | VK Services, LLC | 4% | SCHEDULE 13G/A |
| 2026-08-14 | Cormorant Asset Management, LP | 5.38% | SCHEDULE 13G/A |
Questions about who owns BioAge Labs, Inc.
Who owns BioAge Labs, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of BioAge Labs, Inc.: Kristen Fortney (7.2%, Schedule 13G/A, filed 2026-02-13), Cormorant Asset Management, LP (5.38%, Schedule 13G/A, filed 2026-08-14) and BlackRock, Inc. (5.03%, Schedule 13G, filed 2026-04-27).
Who are the largest shareholders of BioAge Labs, Inc.?
By the share each holder's latest filing reports, the largest holders of BioAge Labs, Inc. on this page are Kristen Fortney (7.2%), Cormorant Asset Management, LP (5.38%) and BlackRock, Inc. (5.03%).
When did Kristen Fortney buy into BioAge Labs, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Kristen Fortney on this page is the Schedule 13G/A, filed 2026-02-13, reporting 7.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for BioAge Labs, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 26, 2024 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| September 25, 2024 | IPO filing, Form S-1/A | $17 to $19 a share | IPO filings | Source |
| September 18, 2024 | IPO filing, Form S-1/A | $17 to $19 a share | IPO filings | Source |
| September 3, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for BioAge Labs, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.